Cases & Deals

  • Home
  • Practices
  • NeuExcell develops global patent portfolios related to gene therapies for neural injuries and neurodegenerative diseases

Share

NeuExcell develops global patent portfolios related to gene therapies for neural injuries and neurodegenerative diseases

September 2025

Client(s) NeuExcell Therapeutics Group

Jones Day is representing NeuExcell Therapeutics Group, a clinical-stage biotechnology company, in the development of global patent portfolios related to next-generation gene therapies to treat neural injuries and neurodegenerative diseases, such as Alzheimer's disease, stroke, and glioma, by leveraging its proprietary in situ neural regeneration platform.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.